UDP-400

UDP-400 is an early-stage (discovery) therapeutic formulation being developed by Cyclarity Therapeutics. It is based on the company's proprietary cyclodextrin platform, which specializes in engineering macrocyclic oligosaccharides to capture and remove specific target molecules. UDP-400 is specifically categorized as a "negative nutrition" formulation intended for "treatment support." While the exact molecular target has not been publicly disclosed, the "negative nutrition" designation suggests a mechanism involving the sequestration or clearance of specific dietary or metabolic components to mitigate their pathological effects or provide supportive care.